Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1722-1723 |
| Number of pages | 2 |
| Journal | Haematologica |
| Volume | 91 |
| Issue number | 12 |
| Publication status | Published - Dec 2006 |
Cite this
}
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. / Wu, Ka Lung; Beksac, Meral; Van Droogenbroeck, Jan; Amadori, Sergio; Zweegman, Sonja; Sonneveld, Pieter.
In: Haematologica, Vol. 91, No. 12, 12.2006, p. 1722-1723.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma
AU - Wu, Ka Lung
AU - Beksac, Meral
AU - Van Droogenbroeck, Jan
AU - Amadori, Sergio
AU - Zweegman, Sonja
AU - Sonneveld, Pieter
PY - 2006/12
Y1 - 2006/12
N2 - Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.
AB - Arsenic trioxide induces growth inhibition and apoptosis in multiple myeloma cell lines. Reducing glutathione by ascorbic acid may enhance the efficacy of arsenic trioxide. Here we report the results of an international multi-center study of arsenic trioxide in combination with ascorbic acid and dexamethasone as treatment for patients with advanced multiple myeloma.
KW - Arsenic trioxide
KW - Multiple myeloma
KW - Single nucleotide polymorphisms
M3 - Article
VL - 91
SP - 1722
EP - 1723
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 12
ER -